ESMO 2017 I I TUMORI CEREBRALI. Dr. Tiziana Falbo Oncologia medica Istituto Neurotraumatologico Italiano Grottaferrata (Roma)
|
|
- Christiana Preston
- 5 years ago
- Views:
Transcription
1 ESMO 2017 I I TUMORI CEREBRALI Dr. Tiziana Falbo Oncologia medica Istituto Neurotraumatologico Italiano Grottaferrata (Roma)
2 Introduction What is a low- grade glioma Weller, Nat Rev Primers 2015 Ostrom, neuro Oncol, 2014 (1)Shaw, Neurosurg, 2008 Buckner, NEJM 2016 (2)Stupp, NEJM 2005
3 WHO 2016 Update : «Integrated diagnosis «Histological Criteria & grade+ Molecular Markers
4 The (long standing) standard of care for GBM Stupp et al. New Eng J Med Weller et al. Lancet Oncol. 2017
5 A decade of negative GBM drug trials Chinot et al. New Eng J Med Stupp et al. Lancet Oncol 2014 Weller et al. Lancet Oncol 2017
6
7 Highlight topics in Madrid Regorafenib in recurrent glioblastoma - Safety of nivolumab with RT ± TMZ in newly diagnosed glioblastoma - EGFR amplification rate in glioblastoma
8 REGOMA: a randomized, multicenter, controlled openlabel phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients Lombardi Giuseppe 1, De Salvo Gian Luca 2, Brandes A. Alba 3, Eoli Marica 4, Rudà Roberta 5, Faedi Marina 6, Lolli Ivan 7, Pace Andrea 8, Rizzato Simona 9, Germano Domenico 10, Pasqualetti Francesco 11, Farina Miriam 2, Magni Giovanna 2, Pambuku Ardi 1, Bergo Eleonora 1, Cabrini Giulio 12, Indraccolo Stefano 13, Gardiman Marina P. 14, Zagonel Vittorina 1 1 Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; 2 Clinical Trials and Biostatistics Unit, IOV-IRCCS, Padua, Italy; 3 Medical Oncology Department, USL-IRCCS Scienze Neurologiche, Bologna, Italy; 4 Besta Institute, Milano, Italy; 5 Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Torino, Italy; 6 Medical Oncology Unit, IRST-IRCCS, Meldola, Italy; 7 Medical Oncology Unit-IRCCS, Castellana Grotte, Bari, Italy; 8 Neuroncology Unit, Regina Elena, Roma, Italy; 9 Medical Oncology Unit, Udine, Italy; 10 Medical Oncology Unit, Benevento, Italy; 11 Radiotherapy Unit, Pisa, Italy; 12 Molecular Pathology Unit, Verona, Italy; 13 Immunology and Molecular Oncology Unit, IOV-IRCCS, Padua, Italy; 14 Pathology Department, Padova, Italy Regione del Veneto
9 Background
10 Regorafenib a pan kinase inhibitor Inhibition of multiple tyrosine kinases FGFR, Ang-2, VEGFR, KIT Inhibits in preclinical model tumor vasculature/ angiogenesis tumor growth Safe and effective in metastatic colon-rectal cancer 1, hepatocellular carcinoma(2) and GIST(3) patients Regorafenib inhibits tumor vasculature and tumor growth in a rat GS9L glioblastoma model 4 1 Grothey et al. Lancet Bruix et al. Lancet Demetri et al. Lancet Wihelm SM et al. Int J Cancer 2011
11 REGOMA - A randomized, multicenter, controlled open-label phase II clinical trial rgbm after RT/TMZ PD by RANO criteria at least 12 weeks after completion of radiotherapy, unless the recurrence is outside the radiation field or has been histologically documented At least 1 bi-dimensionally measurable target lesion with 1 diameter of at least 10mm Histologically confirmed GBM ECOG PS 0-1 (KPS 70) R 1:1 Regorafenib 160mg/die (3 weeks on, 1 week off) Lomustine 110mg/m2 day1 (every 6 weeks) Treat until PD (RANO criteria) Stratification factors: center and surgery at recurrence Study location: 10 centers in Italy
12 Objectives of the study Primary Objective Overall Survival (OS) Secondary Objectives 6-month Progression Free Survival (6m-PFS) (assessed by RANO criteria) Disease control rate (DCR) Objective Response Rate (ORR) Safety (assessed by CTCAE v4.0) Quality of Life (assessed by EORTC QoL C30 and BN-20) Exploratory Analyses Analysis of angiogenic and metabolic tissue biomarkers as possible predictors of response to regorafenib
13 Baseline Patient Characteristics
14 Overall Survival Arm Total Failed Regorafenib Lomustine Median OS months (95%CI) 6.5 ( ) 5.5 ( ) 6-month OS (95%CI) 55.6 ( ) 43.6 ( ) 12-month OS (95%CI) 36.8 ( ) 12.7 ( ) Log-Rank p-value 1-side Hazard Ratio (80%CI) 0.64 ( )
15 Progression-free survival Arm Total Failed Regorafenib Lomustine Median PFS, months (95%CI) 2.0 ( ) 1.9 ( ) 3-month PFS (95%CI) 44.1% ( ) 25% ( %) 6-month PFS (95%CI) 15.5% ( ) 8.3% ( %) Log-Rank p-value Hazard Ratio (95%CI) 0.69 ( )
16 Response Rates Regorafenib Lomustine Complete Response 1.7% 1.8% Partial Response 3.4% 1.8% Objective Response Rate 5.1% 3.6% Stable Disease 39% 17.5% Disease Control Rate 44.1% 21.1% Progressive Disease 55.9% 78.9% Chi-square test p-value=0.0083
17 Post progression treatment
18 SAFETY
19 Conclusions Primary endpoint of a better OS estimate with regorafenib versus lomustine was met This was a large academic, multicenter, randomized trial in patients with relapsed glioblastoma reporting for the first time on regorafenib activity and efficacy Regorafenib adverse events were manageable and expected. Quality of life analyses are ongoing Regorafenib efficacy should be confirmed in a subsequent randomized phase 3 study
20 Nivolumab in Combination With Radiotherapy ± Temozolomide: Updated Safety Results From CheckMate 143 in Patients With Methylated or Unmethylated Newly Diagnosed Glioblastoma Michael Lim, 1,a Antonio Omuro, 2,a Gordana Vlahovic, 3 David A. Reardon, 4 Solmaz Sahebjam, 5 Timothy Cloughesy, 6 Joachim Baehring, 7 Nicholas Arthur Butowski, 8 Von Potter, 9 Ricardo Zwirtes, 9 Prashni Paliwal, 9 Michael Carleton, 9 John Sampson, 3,b Alba A. Brandes 10,b 1 The Johns Hopkins Hospital, Baltimore, MD; 2 Memorial Sloan Kettering Cancer Center, New York, NY; 3 Duke University Medical Center, Durham, NC; 4 Dana-Farber Cancer Institute and Harvard University School of Medicine, Boston, MA; 5 Moffitt Cancer Center and Research Institute, Tampa, FL; 6 University of California Los Angeles, Los Angeles, CA; 7 Yale School of Medicine, New Haven, CT; 8 University of California San Francisco, San Francisco, CA; 9 Bristol-Myers Squibb, Princeton, NJ; 10 AUSL-IRCCS Institute of Neurological Sciences, Bologna, Italy a Co-lead authors. b Co-senior authors.
21 S 1 2 Antigen release and antigen uptake Tumour cell Antigenpresenting cell Antigen-presenting cell migration and lymph drainage Cervical lymph node Glioblastoma tumour 5 4 Figure 1 Overview of the immune response and major immune checkpoint molecules in the immune cycle of glioblastoma. Antigens released from degenerating tumour cells are taken up by antigen-presenting Nature cells, Reviews microglia and Neurology macrophages (1). Antigens are trafficked to lymph nodes via migration of antigen-presenting cells, and via drainage through lymphatic vessels in the meningeal sinuses (2). In the lymphatic tissues, antigen presentation and T-cell priming takes place. This interaction is tightly regulated by a multitude of co-inhibitory (CTLA4) and co-stimulatory (CD80, CD86, CD28) immune checkpoint molecules, and could be modulated by specific therapeutic antibodies, such as the CTLA4 inhibitor ipilimumab (3). Activated T cells reach the tumour via the blood stream and migration through the blood brain or blood tumour barrier (4). Tumour-associated immunosuppressive factors, including immune checkpoint molecules, inhibit tumour cell destruction by T cells. PDL1 is expressed on tumour cells and microglia and inhibits T cells via binding to PD1. PD1 PDL1 inhibitors (for example, nivolumab, pembrolizumab) block this immunosuppressive mechanism and thereby increase tumour cell lysis by The inflammatory microenvironment in glioblastoma Interaction between T cell and tumour cell or antigen-presenting cell Tumour cell PD1 PDL1 inhibitor T-cell traff c with migration through the blood brain barrier and blood tumour barrier 3 Antigen presentation and T-cell priming CTLA4 inhibitor + T cell Microglia Antigen CD80/ 86 CD28 TCR CTLA4 MHC PDL1 PD1 Tight regulation of inflammatory processes in the CNS Low density of tumor associated lymphocytes in glioblastoma compared to brain metastases 1 Activation of immune system under investigation in gliomas: dendritic cells, vaccination, Immune-checkpoint inhibitors, CAR-T-cells Preusser et al, Nat Rev 2015
22 Cohorts 1c and 1d Study Design CheckMate 143: Nivolumab With RT ± TMZ in Newly Diagnosed GBM Newly Diagnosed GBM a Cohort 1c Part A (non-randomized): Any MGMT methylation status Part B (randomized to 1c or 1d): Unmethylated MGMT status Cohort 1d Part A (non-randomized); Part B (randomized to 1c or 1d): Unmethylated MGMT status Standard RT (60 Gy) b + Concurrent TMZ (75mg/m 2 daily) Nivolumab 3 mg/kg Q2W Adjuvant TMZ ( mg/m 2 5/28 d for 6 cycles) Weeks Standard RT (60 Gy) b Nivolumab 3 mg/kg Q2W Treatment until: Confirmed disease progression Unacceptable toxicity Discontinuation due to other reason Follow-up: Safety for 100 days Progression Survival every 3 months Primary Endpoint: Safety and tolerability (CTCAE v4.0) Data Cutoff for Analysis: July 13, 2017
23 Safety Summary CheckMate 143: Nivolumab With RT ± TMZ in Newly Diagnosed GBM Grade 3 4 a AE, adverse event; SAE, serious adverse event; TRAE, treatment-related adverse event. a Per CTCAE v4.0.
24 Conclusions CheckMate 143: Nivolumab With RT ± TMZ in Newly Diagnosed GBM Nivolumab in combination with RT ± TMZ was well tolerated, with no new safety signals The use of TMZ in combination with nivolumab and RT did not lead to significant additional safety events, other than those known to occur with TMZ alone The cohort not receiving TMZ did not show any significant additional immune-mediated AEs The incidence of grade 3 4 neurological TRAEs was relatively low (< 5%) and consistent with our previous experience in GBM These results suggest that nivolumab in combination with RT and nivolumab in combination with RT and TMZ are safe for further clinical evaluation in patients with newly diagnosed GBM 24
25 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION RATES OBSERVED IN SCREENING PATIENTS FOR RANDOMIZED CLINICAL TRIALS IN GLIOBLASTOMA Martin J. van den Bent 1, Lisa Roberts-Rapp 2, Peter Ansell 2, James Lee 3, Jim Looman 2, Earle Bain 2, Christopher Ocampo 2, Kyle D. Holen 2, Erica J. Gomez 2, Andrew B. Lassman 4 1 Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, NL; 2 AbbVie Inc., North Chicago, IL, USA; 3 Abbott Molecular Inc., Des Plaines, IL, USA; 4 Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA esmo.org
26 EGFR signals EGFR abnormalities in glioblastoma EGFR amplification EGFR protein expression EGFR viii CEP 7 signals - Controversial association of EGFR abnormalities and prognosis - Treatment target for - EGFR viii: Rindopepimut vaccination: negative phase III trial - EGFR amplification: antibody-drug conjungate ABT-414/Depatux-m
27 EGFR tyrosine Kinase inhibitors are (almost) inactive in glioblastoma (apparently) irrespective of EGFR status
28 Antibody-drug conjugate Depatux-M (ABT-414)
29 INTELLANCE 1 Study Design M13-813/RTOG 3508, Phase II/III, 1L GBM Patient Population Histologically confirmed de novo GBM (primary) or gliosarcoma Tumor demonstrates EGFR amplification Chemoradiation therapy start within 7 wks of diagnosis Karnofsky performance score 70 1:1 Randomization Placebo-controlled N = 360 RT/TMZ RT/TMZ N = 360 RT/TMZ + depatux-m INTELLANCE 2 Study Design M14-483/EORTC-1410-BTG, Phase II, 2L GBM Patient Population Histological confirmed recurrent de novo (primary) GBM Tumor demonstrates EGFR amplification 1 line of chemotherapy WHO score 0-2 No prior EGFR- or EGFRvIII-directed therapy 1:1:1 Randomization Open-label N = 80 Arm 1: depatux-m + TMZ N = 80 Arm 2: depatux-m N = 80 Arm 3: Lomustine or TMZ
30 Study sites INTELLANCE 1 INTELLANCE 2
31 Pooled INTELLANCE 1/2 screening results ROW EGFRamplified Nonamplified Total Positive Africa % Americas % Asia % Europe % Middle East % Oceania % Total %
32 EGFR amplification in glioblastoma EGFR amplification is present in 52% of patients with GBM Largest cohort ever screened (2090 patients) Lower EGFR amplification rate in patients with GBM from Asia (35%) INTELLANCE 1 and INTELLANCE 2 explore the antibody-drug conjugate depatuxizumab mafodotin (depatux-m, ABT-414) in newly diagnosed and recurrent glioblastoma
33 Take home messages - Regorafenib showed signs of activity in recurrent glioblastoma - Nivolumab in combination with RT ± TMZ is well tolerated - EGFR amplifications are a potential treatment target in glioblastoma, but are less common in the Asian patient population
34 Thanks for your attention!
Glioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationRINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA
RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA MULTIFORM GEINO 2014 Dra Estela Pineda Madrid Hospital Clínic Barcelona EGFRvIII in glioblastoma multiform The most common mutation of EGFR in GBM Expressed in 30%
More informationImmuno-Oncology. Glioblastoma and CNS tumors 5 July 2016 Siena, Italy
ESMO Preceptorship Programme Immuno-Oncology From the essentials of tumour immunology to clinical application Glioblastoma and CNS tumors 5 July 2016 Siena, Italy Michael Weller Department of Neurology
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationTratamiento sistémico en la enfermedad recurrente. Dr Pedro Salinas Oncología médica
Tratamiento sistémico en la enfermedad recurrente Dr Pedro Salinas Oncología médica Glioblastoma: Mínimos Avances Terapéuticos desde 2005 ESTUDIO AVAGLIO Stupp + Bevacizumab/placebo Cual es el mejor tratamiento
More informationNivolumab nel carcinoma renale metastatico: esperienza italiana
Nivolumab nel carcinoma renale metastatico: esperienza italiana Ugo De Giorgi Istituto Tumori Romagna IRST IRCCS Meldola on behalf of the Italian EAP RCC Group Real world data from the Italian expanded
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationImmuno-Oncology. Glioblastoma 3 November 2016 Zurich, Switzerland
ESMO Preceptorship Programme Immuno-Oncology From the essentials of tumour immunology to clinical application Glioblastoma 3 November 2016 Zurich, Switzerland Michael Weller Department of Neurology & Brain
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationSpecial Situation: Brain metastases
ESMO Advanced Course on Unsolved Questions in Immuno-Oncology February 16-17 2018, Amsterdam, Netherlands Special Situation: Brain metastases Matthias Preusser, MD Associate Professor of Medicine Department
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationAntibody Drug Conjugates in Glioblastoma?
Antibody Drug Conjugates in Glioblastoma? EORTC-EANO-ESMO Conference 2015 Trends in Central Nervous System Malignancies March 27, 2015 Istanbul, Turkey David A. Reardon, MD Clinical Director Center for
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationOverall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario
More informationAntiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /
Antiangiogenic drugs in unresectable glioblastoma Dra. Carmen Balañá. / Outcome for unresectable GBM Overall survival for unresectable GBM without further treatment is: 3 months at most. Radiotherapy increases
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationClinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer
Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,
More informationMarizomib (MRZ): Brain Penetrant Irreversible Pan-Proteasome Inhibitor
MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY Daniela Bota, MD, PhD 1, Annick Desjardins, MD,
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationAIOM GIOVANI Perugia, Luglio 2017
AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationNCCN Guidelines for Central Nervous System Cancers V Follow-Up on 02/23/18
GLIO-3 and GLIO-4 Submission from Novocure Inc. (12/19/17 and 9/7/17) Please consider adding tumor treating fields in combination with temozolomide for the treatment of adult patients with newly diagnosed,
More informationfrom temozolomide to tumor treating fields a journey of successes and failures
from temozolomide to tumor treating fields a journey of successes and failures Roger Stupp, MD Co-Director Brain Tumor Institute Dept. of Neurological Surgery Chief, Div. of Neuro-Oncology Dept. of Neurology
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for Glioblastoma: CMV-LAMP-Vax Executive Summary Executive Summary pp65-lamp-vax First Line Therapy for Glioblastoma Multiforme
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationDurable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Lawrence G. Lum, MD, DSc Karmanos Cancer Institute and Wayne State University Advances in Cancer Immunotherapy
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationCHECKPOINT INHIBITORS IN GLIOBLASTOMA
VII Symposium Educacional GEINO Madrid, 3-4 diciembre 2015 CHECKPOINT INHIBITORS IN GLIOBLASTOMA Juan M Sepúlveda Sánchez Unidad Multidisciplinar de Neurooncología Hospital 12 de Octubre Cancer Inmunotherapy
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationImmunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience
Immunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience Derek Wainwright, PhD Assistant Professor Departments of Neurological Surgery, Microbiology-Immunology
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationTemozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma
Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Correlation With MGMT Promoter Methylation Status Alba A. Brandes, MD 1 ; Enrico Franceschi, MD 1 ; Alicia Tosoni,
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationUniversity of Colorado Cancer Center Brain Disease Site Schema
GBM FIRST LINE 18 0376/Kazia Phase 2a study (Part 1): A phase 2a study to evaluate the safety, pharmacokinetics and clinical activity of the PI3K/mTOR inhibitor GDC 0084 administered to patients with glioblastoma
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More information1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016
Lead team presentation Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971] 1 st Appraisal Committee meeting Background
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More information2011 Oncology Highlights News from ASCO 2011:
2011 Oncology Highlights News from ASCO 2011: Malignant Glioma David A. Reardon, M.D. Clinical Director Center for Neuro-Oncology Dana-Farber Cancer Institute 450 Brookline Avenue SW-430 Boston, MA 02215
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationConcurrent Chemo- and Radiotherapy for Ororpharynx Cancer
Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer Faye Johnson MD, PhD Associate Professor Thoracic/Head and Neck Medical Oncology August 2017 Objectives Review data that support concurrent chemo-
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationUniversity of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
ipilimumab aligned with patient values. Although few patients had direct experience using this combination agent, patients indicated that side effects associated with nivolumab plus ipilimumab were few
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationGEINO TRIALS. RESULTS IN 2015
VII Symposium Educacional GEINO Madrid, 3-4 diciembre 2015 GEINO TRIALS. RESULTS IN 2015 Juan M Sepúlveda Sánchez Unidad Multidisciplinar de Neurooncología Hospital 12 de Octubre GEINO-11: A Prospective
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationPresented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9 12, 2017; Atlanta, GA, USA
65 Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 25 Study Jonathon B. Cohen, 1 Andreas
More informationA Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM)
A Phase II Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM) Morten Mau-Sorensen 1, Scott Plotkin 2, Patrick Wen 3, Andrew
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationCancer Drugs Fund. Managed Access Agreement. Nivolumab for previously treated nonsquamous non-small-cell lung cancer
Cancer Drugs Fund Managed Access Agreement Nivolumab for previously treated nonsquamous non-small-cell lung cancer NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data Collection Arrangement
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationpost Chicago 2016: Thoraxonkologie Helge Bischoff Thoraxonkologie, Thoraxklinik Universität Heidelberg
post Chicago 2016: Thoraxonkologie Helge Bischoff Thoraxonkologie, Thoraxklinik Universität Heidelberg Post Chicago 2016: Thoraxonkologie Immuntherapie SCLC Mesotheliom Nachsorge Pembro/ Carbo/Taxol Pembro/
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More information